Duet BioTherapeutics

Duet BioTherapeutics is a biopharmaceutical company that is part of Scopus BioPharma, focused on developing targeted immunotherapies to combat treatment-resistant cancers. The company was founded in 2019 and is headquartered in the United States. Duet BioTherapeutics is pioneering a new category of bispecific oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. This approach aims to activate antigen-presenting cells, thus removing the immunosuppressive shield around the tumor and initiating T cell-mediated immune responses to effectively eradicate cancer cells. The company recently received a Debt Financing investment on 08 March 2023, demonstrating ongoing investor interest in its innovative immunotherapy solutions for challenging cancers. The specific investors involved in this round of financing have not been disclosed. Duet BioTherapeutics operates within the biopharma, biotechnology, and health care industries, positioning themselves at the forefront of advancing cancer treatment through sophisticated immunotherapies.